On the other hand, LEE001 synergizes with glucocorticoids and the mTOR inhibitor everolimus both in vitro and in vivo, in T-ALL xenograft models established from MOLT4 and MOLT16 [47], suggesting that CDK4/6 inhibitors may emerge as a potential strategy in R/R T-ALL. The gene discussed is CDK4; the disease is acute lymphoblastic leukemia.